TABLE 2.

In vitro activity of HMR 3647 against macrolide- and lincosamide-resistant bacterial isolates

Microorganism (total no. of isolates tested)	Resistance pheno- typea	No. of isolatesb	HMR 3647 MIC (μg/ml)		% of isolates for which MIC was ≤1.0 μg/mlc
			50%	90%
Staphylococcus aureus (515)	Erys	265	≤0.12	≤0.12	100
	Eryr	249	2.0	8.0	23
	Clins	330	≤0.12	≤0.12	100
	Clinr	185	>16	>16	26
Coagulase-negative Staphylococcus spp. (477)	Erys	198	≤0.12	≤0.12	100
	Eryr	276	0.5	>16	51
	Clins	335	≤0.12	0.25	100
	Clinr	138	>16	>16	3
Streptococcus pneumoniae (545)	Erys	445	≤0.12	≤0.12	100
	Eryi	37	≤0.12	≤0.12	100
	Eryr	63	≤0.12	0.25	100
	Clins	514	≤0.12	≤0.12	100
	Clinr	30	≤0.12	≤0.12	100
Nonpneumococcal Streptococcus spp. (452)	Erys	349	≤0.12	≤0.12	100
	Eryi	51	≤0.12	≤0.12	100
	Eryr	52	≤0.12	0.25	98
	Clins	427	≤0.12	≤0.12	100
	Clinr	24	≤0.12	≤0.12	96
Enterococcus faecalis (359)	Erys	58	≤0.12	≤0.12	100
	Eryi	140	≤0.12	≤0.12	100
	Eryr	161	0.25	4.0	94
	Clini	30	≤0.12	≤0.12	97
	Clinr	324	≤0.12	2.0	87
Enterococcus faecium (94)	Eryi	20	≤0.12	≤0.12	100
	Eryr	74	4.0	8.0	14
	Clins	16	≤0.12	≤0.12	100
	Clinr	76	2.0	8.0	23

^aStrains were susceptible (s), intermediately susceptible (i), or resistant (r) to erythromycin (Ery) or clindamycin (Clin). For both drugs, MIC breakpoints for susceptibility and resistance, respectively, were ≤4.0 and ≥16 μg/ml for tests of enterococci, ≤4.0 and ≥32 μg/ml for tests of staphylococci, and ≤0.5 and ≥2.0 μg/ml for tests of pneumococci and other streptococci. 

^bPhenotypes that were represented by fewer than 10 isolates are excluded from this table. 

^cPercent of strains susceptible to ≤1.0 μg of HMR 3647 per ml.